News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Schering-Plough Corporation Anesthesia Drug Gets Mixed FDA Review
March 10, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON (Reuters) - A Schering-Plow Corp drug to reverse the effects of anesthesia appears to be generally safe, U.S. regulatory staff said, but they questioned how the company defined effectiveness in a key study.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Food and Drug Administration (FDA)
Organon
MORE ON THIS TOPIC
Lung Cancer
AbbVie’s ADC Nabs Accelerated Approval for Lung Cancer
May 15, 2025
·
2 min read
·
Tristan Manalac
Podcast
Trump’s Drug Pricing Policy, Prasad’s CBER Nod, Bayer’s Layoffs and Galapagos’ Next Chapter
May 14, 2025
·
2 min read
·
Heather McKenzie
Drug pricing
CMS Prepares for Third Cycle of Drug Negotiations as Trump Intensifies Push To Lower Prices
May 13, 2025
·
3 min read
·
Tristan Manalac
Pharmacy benefit managers
Trump’s Most Favored Nation Policy Sparks PBM Selloff
May 13, 2025
·
2 min read
·
Tristan Manalac